FOLH1 and prostate cancer: Compared to the reference DOTA conjugated [212Pb]Pb-PSMA-617 construct, [212Pb]Pb-NG001, a TCMC-conjugated PSMA ligand, demonstrated comparable tumor uptake and reduced kidney retention when evaluated in C4-2 (PSMA-expressing prostate cancer cell line) bearing mice 90,91​.